Exscientia Plc Sponsored Adr (EXAI) has released an update.
Exscientia Plc, a leader in AI-powered drug design, reported progress in its drug development pipeline for 2023, including advancements in oncology targets and collaborations with large pharma partners. The company is preparing to progress its CDK7 inhibitor and LSD1 inhibitor through clinical trials, while also expanding its technological capabilities with a new automated discovery laboratory. Despite a decrease in revenue compared to the previous year, Exscientia remains financially stable with sufficient funds to operate well into 2026.
For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.
